A delayed clinical trial actually boosted Bristol Myers Squibb’s stock. Here’s why.
Bullish
50.0
Bristol Myers’ stock rallied Wednesday as investors maintained high hopes for Cobenfy as an Alzheimer’s treatment, even though the outcome of a late-stage trial has been delayed.
Pulse AI Analysis
Pulse analysis not available yet. Click "Get Pulse" above.
This analysis was generated using Pulse AI, Glideslope's proprietary AI engine designed to interpret market sentiment and economic signals. Results are for informational purposes only and do not constitute financial advice.
